scholarly journals Case Report: Pulmonary sarcomatoid carcinoma in a female patient from Nepal

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 723
Author(s):  
Anirudra Devkota ◽  
Amrit Paudel ◽  
Simit Sapkota ◽  
Subash Pandit ◽  
Aashish Baniya
Keyword(s):  
Ct Scan ◽  
Sarcomatoid Carcinoma ◽  
Lower Lobe ◽  
Small Cell ◽  
Chronic Obstructive ◽  
Shortness Of Breath ◽  
Small Cell Lung ◽  
Dismal Prognosis ◽  
History Of ◽  
Pulmonary Sarcomatoid Carcinoma

Sarcomatoid carcinoma of the lung is an uncommon subtype of non-small-cell lung cancer (NSCLC). Even in the early stages, pulmonary sarcomatoid carcinoma (PSC) has a dismal prognosis when compared to other kinds of NSCLC with a mean survival of 9–12 months and a five-year survival rate of around 20%. We present the case of a 68-year-old woman with a two-month history of shortness of breath and cough. Initial computed tomography (CT) scan showed features of interstitial lung disease with chronic obstructive airway changes. After 34 months, the patient’s condition worsened with newer complaints of sore throat and hemoptysis. A repeat CT scan showed a ∼49x38x59mm size lesion in the superior segment of the left lower lobe. A core needle biopsy was performed, which revealed tumor cells consisting of irregular tubules and sarcomatoid components. The patient was started on chemotherapy. Unfortunately, she succumbed to her disease. Our case highlights the aggressiveness of PSC.

scholarly journals Sarcomatoid Carcinoma of the Lung: A Rare and Unfortunate Disease

2019 ◽  
Vol 4 (4) ◽  
Keyword(s):  
Sarcomatoid Carcinoma ◽  
The Body ◽  
Chronic Obstructive ◽  
Overall Survival Rate ◽  
Past Medical History ◽  
Poor Overall Survival ◽  
Obstructive Pulmonary Disease ◽  
History Of ◽  
Pulmonary Sarcomatoid Carcinoma ◽  
Rare Malignancy

Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare malignancy with a poor overall survival rate. Sarcomatoid tumors (SC) can arise out of many organs in the body and are generally rare but primary PSC’s are among the rarest. Of all lung tumors, PSC’s represent less than 1%. Our case presents a male with a past medical history of chronic obstructive pulmonary disease (COPD) who presents with a pleural effusion secondary to PSC.

scholarly journals Response to Gefitinib/Crizotinib Combination in a Pulmonary Sarcomatoid Carcinoma Patient Harboring Concurrent EGFR Mutation and MET Amplification

2021 ◽  
Author(s):  
Xiaomeng Wang ◽  
Jie Cao ◽  
Shui Cao ◽  
Weijiao Du ◽  
Weihong Zhang
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Sarcomatoid Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Carcinoma Patient ◽  
Met Amplification ◽  
Pulmonary Sarcomatoid Carcinoma

Pulmonary sarcomatoid carcinoma; non-small cell lung cancer; EGFR mutation; MET amplification; crizotinib/gefitinib

scholarly journals Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis

2018 ◽  
Vol 11 (3) ◽  
pp. 615-621 ◽  
Author(s):  
Massimiliano Salati ◽  
Cinzia Baldessari ◽  
Fiorella Calabrese ◽  
Giulio Rossi ◽  
Elisa Pettorelli ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Brain Lesion ◽  
Sarcomatoid Carcinoma ◽  
Small Cell ◽  
Dramatic Improvement ◽  
Small Cell Lung ◽  
Cancer Subtypes ◽  
Pulmonary Sarcomatoid Carcinoma

Background: Pulmonary sarcomatoid carcinoma is a rare, poorly differentiated, and highly aggressive type of non-small cell lung cancer. High tumor mutational burden and PD-L1 overexpression make it an excellent candidate for immunotherapy. Objectives and Method: We presented the case of a patient who underwent left inferior lobectomy with concurrent right paravertebral muscular metastasectomy for an infiltrative neoplastic mass, whose final diagnosis was consistent with stage IV pulmonary sarcomatoid carcinoma. He received first- and second-line chemotherapy without any benefit. Since March 2016, he has been treated with the anti-PD1 agent nivolumab with a dramatic improvement of symptoms, disappearance of a brain lesion, and partial response on other metastatic sites. He tolerated the treatment well and is still responding after 22 months from the beginning. Results and Conclusions: In very lethal non-small cell lung cancer subtypes such as the sarcomatoid variants, high tumor burden and deteriorated general conditions should not preclude, at least in some cases, the use of immunotherapy. Anti-PD1 may also have a reliable role in disease control in the brain. Lastly, the strong rationale behind sarcomatoid histology should further prompt trials exploring immunotherapeutic approaches in this subset of non-small cell lung cancer.

scholarly journals Transformation of Two Cases of Lung Adenocarcinoma into Pulmonary Sarcomatoid Carcinoma following Treatment

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Zhenyu Yang ◽  
Yinfang Shen ◽  
Junhong Jiang ◽  
Ziyi Liu ◽  
Chuanyong Mu
Keyword(s):  
Lung Cancer ◽  
Drug Resistance ◽  
Squamous Cell Carcinoma ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Sarcomatoid Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pulmonary Sarcomatoid Carcinoma

Accumulating evidence shows that histologic transformation is involved in the drug resistance of lung cancer. Moreover, it is common for lung adenocarcinoma to transform into small-cell lung cancer or squamous cell carcinoma; however, clinical cases with sarcomatoid transformation have been rarely reported. Thus, both the diagnosis and treatment of lung adenocarcinoma with sarcomatoid transformation remain difficult. Here, we discuss two patients with lung adenocarcinoma with sarcomatoid transformation—analyzing the diagnosis, clinical features, immunohistochemical characteristics, therapy, and prognosis—with the hope that this report will be used as a reference for future treatment of these patients.

scholarly journals History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 998
Author(s):  
Chiara Lazzari ◽  
Aurora Mirabile ◽  
Alessandra Bulotta ◽  
Maria Grazia Viganó ◽  
Francesca Rita Ogliari ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Time ◽  
Small Cell ◽  
Review Of The Literature ◽  
Small Cell Lung ◽  
Extensive Disease ◽  
History Of ◽  
Line Standard

Several trials have tried for decades to improve the outcome of extensive disease small cell lung cancer (ED-SCLC) through attempts to modify the standard treatments. Nevertheless, platinum/etoposide combination and topotecan have remained respectively the first and the second line standard treatments for the last 40 years. With the advent of immunotherapy, this scenario has finally changed. Our review aims to provide an overview of the primary studies on the actual therapeutic strategies available for ED-SCLC patients, and to highlight emerging evidence supporting the use of immunotherapy in SCLC patients.

Sign in / Sign up

Export Citation Format

Share Document